Menu
Back to User profile » Dr Kai-Michael Beeh
Papers published by Dr Kai-Michael Beeh:
Characteristics of Users and New Initiators of Single- and Multiple-Inhaler Triple Therapy for Chronic Obstructive Pulmonary Disease in Germany
Beeh KM, Rothnie KJ, Claussen J, Hardtstock F, Knapp RK, Wilke T, Czira A, Compton C, Ismaila AS
International Journal of Chronic Obstructive Pulmonary Disease 2024, 19:945-956
Published Date: 17 April 2024
Real-World Effectiveness of Fluticasone Furoate/Umeclidinium/Vilanterol Once-Daily Single-Inhaler Triple Therapy for Symptomatic COPD: The ELLITHE Non-Interventional Trial
Beeh KM, Scheithe K, Schmutzler H, Krüger S
International Journal of Chronic Obstructive Pulmonary Disease 2024, 19:205-216
Published Date: 17 January 2024
Cost-Effectiveness of Single- versus Multiple-Inhaler Triple Therapy in a UK COPD Population: The INTREPID Trial
Halpin DM, Kendall R, Shukla S, Martin A, Shah D, Midwinter D, Beeh KM, Kocks JWH, Jones PW, Compton C, Risebrough NA, Ismaila AS
International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:2745-2755
Published Date: 25 October 2022
Maximizing Adherence and Gaining New Information For Your Chronic Obstructive Pulmonary Disease (MAGNIFY COPD): Study Protocol for the Pragmatic, Cluster Randomized Trial Evaluating the Impact of Dual Bronchodilator with Add-On Sensor and Electronic Monitoring on Clinical Outcomes
Price D, Jones R, Pfister P, Cao H, Carter V, Kemppinen A, Holzhauer B, Kaplan A, Clark A, Halpin DMG, Pinnock H, Chalmers JD, van Boven JF, Beeh KM, Kostikas K, Roche N, Usmani OA, Mastoridis P
Pragmatic and Observational Research 2021, 12:25-35
Published Date: 24 May 2021
Comparison of Dry-Powder Inhaler and Pressurized Metered-Dose Inhaler Formulations of Extrafine Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrronium in Patients with COPD: The TRI-D Randomized Controlled Trial
Beeh KM, Kuna P, Corradi M, Viaud I, Guasconi A, Georges G
International Journal of Chronic Obstructive Pulmonary Disease 2021, 16:79-89
Published Date: 14 January 2021
Indacaterol acetate/mometasone furoate provides sustained improvements in lung function compared with salmeterol xinafoate/fluticasone propionate in patients with moderate-to-very-severe COPD: results from a Phase II randomized, double-blind 12-week study
Beeh KM, Kirsten AM, Tanase AM, Richard A, Cao W, Hederer B, Beier J, Kornmann O, van Zyl-Smit RN
International Journal of Chronic Obstructive Pulmonary Disease 2018, 13:3923-3936
Published Date: 6 December 2018
Dose–response of an extrafine dry powder inhaler formulation of glycopyrronium bromide: randomized, double-blind, placebo-controlled, dose-ranging study (GlycoNEXT)
Beeh KM, Emirova A, Prunier H, Santoro D, Nandeuil MA
International Journal of Chronic Obstructive Pulmonary Disease 2018, 13:1701-1711
Published Date: 25 May 2018
ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD
Watz H, Troosters T, Beeh KM, Garcia-Aymerich J, Paggiaro P, Molins E, Notari M, Zapata A, Jarreta D, Garcia Gil E
International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:2545-2558
Published Date: 24 August 2017
Effect of ELOM-080 on exacerbations and symptoms in COPD patients with a chronic bronchitis phenotype – a post-hoc analysis of a randomized, double-blind, placebo-controlled clinical trial
Beeh KM, Beier J, Candler H, Wittig T
International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:2877-2884
Published Date: 23 November 2016
Early bronchodilator action of glycopyrronium versus tiotropium in moderate-to-severe COPD patients: a cross-over blinded randomized study (Symptoms and Pulmonary function in the moRnING)
Marin JM, Beeh KM, Clemens A, Castellani W, Schaper L, Saralaya D, Gunstone A, Casamor R, Kostikas K, Aalamian-Mattheis M
International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:1425-1434
Published Date: 28 June 2016
The lung function profile of once-daily tiotropium and olodaterol via Respimat® is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler® (ENERGITO® study)
Beeh KM, Derom E, Echave-Sustaeta J, Grönke L, Hamilton A, Zhai D, Bjermer L
International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:193-205
Published Date: 3 February 2016
Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial
Beeh KM, Singh D, Di Scala L, Drollmann A
International Journal of Chronic Obstructive Pulmonary Disease 2012, 7:503-513
Published Date: 31 July 2012
Long-acting ß-adrenoceptor agonists in the management of COPD: focus on indacaterol
Beier J, Beeh KM
International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:237-243
Published Date: 12 April 2011
Indacaterol: a new once daily long-acting beta2 adrenoceptor agonist
Kai M Beeh, Jutta Beier
Core Evidence 2009, 4:37-41
Published Date: 18 June 2009